(Q46467386)

English

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

scientific article published on 29 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

phase II clinical trial

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

psoriatic arthritis

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

Désirée van der Heijde

5

object named as

Désirée van der Heijde

0 references

4

object named as

Paul Emery

0 references

object named as

John D Isaacs

6

0 references

15

object named as

Paul P Tak

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

Hendrik Schulze-Koops

9

object named as

Hendrik Schulze-Koops

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

author name string

Joachim Sieper

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

Jürgen Braun

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

Georg Dahmen

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

Jürgen Wollenhaupt

8

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

Joseph Kogan

10

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

Shenglin Ma

11

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

Martin M Schumacher

12

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

Arthur P Bertolino

13

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

Wolfgang Hueber

14

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

language of work or name

0 references

publication date

29 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

73

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

349-356

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

IL-17 receptor and its functional significance in psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

Axial disease in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

Assessment of enthesitis in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202646

21 January 2018

Identifiers

10.1136/ANNRHEUMDIS-2012-202646

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23361084

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46467386&oldid=2112953072"